Is sprycel a chemotherapy?
SPRYCEL is the trade name for the generic chemotherapy drug Dasatinib. In some cases, health care professionals may use the trade name SPRYCEL when referring to the generic drug name Dasatinib. Drug Type: SPRYCEL is a targeted therapy.
What type of drug is dasatinib?
Dasatinib is a type of drug called a cancer growth blocker. It works by blocking particular proteins on cancer cells that encourage the cancer to grow. This can help shrink the cancer or stop it growing.
Does Sprycel make you gain weight?
Can Sprycel cause weight gain or weight loss? Yes, weight gain and weight loss were side effects reported in studies of Sprycel. It’s important to note that leukemia (the condition Sprycel is used to treat) can cause weight loss.
How long can you take Sprycel?
Sprycel is used as a long term treatment and in clinical trials has been taken for 5 years. You usually keep on taking it as long as: your tests show it is working well. your condition has not worsened.
What is the target of imatinib?
Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT.
What is the binding energy of imatinib?
Imatinib is known to bind 2400 times less tightly (experimentally measured 4.6 kcal/mol penalty) to the c-SRC form (DFG-in) of tyrosine kinase than to the closely related c-ABL form (DFG-out), even though the X-ray crystal structures of both complexes are very similar.
How long can you take dasatinib?
Is dasatinib a blood thinner?
Dasatinib can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests.
Is dasatinib a targeted therapy?
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is a targeted therapy intended to treat your cancer by binding to the target protein called BTK. BTK is believed to be an important target for treatment of patients with specific gene mutations.
